EMA Recommends Granting a Marketing Authorisation for Aumolertinib By Ogkologos - January 8, 2026 416 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with EGFR-mutated NSCLC Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Zanubrutinib October 26, 2022 How Early Cancer Detection and Diagnosis Saved My Life Twice: A... December 27, 2023 Coping With Cancer Recurrence: My Perspective As Both a Patient and... January 24, 2023 After Breast Cancer Diagnosis, Technology Professor Teaches Computers to Read Mammograms April 11, 2019 Load more HOT NEWS FDA Approves Amivantamab-vmjw for EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung... Trial Results Support Adding Daratumumab to Initial Treatment for Multiple Myeloma No Survival Benefit from Adding Preoperative Chemoradiotherapy to Perioperative Chemotherapy in... Studying Genes and Proteins Together Sheds New Light on Colon Cancer
